Evidence map›Paper›PMID 41108387›Full record

ArticleArchives of microbiology2025

Intranasal phage therapy overcomes antibody neutralization challenges in pulmonary Pseudomonas aeruginosa infections.

Dhammika Leshan Wannigama, Jingping Shao, Hongya Sun, Yangzhong Wang, Cameron Hurst, Peter N Monk, Mohan Amarasiri, Phatthranit Phattharapornjaroen, William Graham Fox Ditcham, Thin Sandi Htun and 17 more

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Recurrent/Refractory Multidrug- and Pre-Multidrug-ResistantClinical pharmacology : advances and applications · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Dhammika Leshan WannigamaDepartment of Infectious Diseases, Faculty of Medicine, Yamagata University, Yamagata, Japan. leshanwannigama@med.id.yamagata-u.ac.jp.
Jingping Shao *Faculty of Pharmacy, Zhejiang Pharmaceutical University, Ningbo, 315100, People's Republic of China.
Hongya Sun *Department of Pharmacy, The Affiliated People's Hospital of Ningbo University, Ningbo, 315100, People's Republic of China.
Yangzhong Wang *Pathogen Hunter's Research Team, Department of Infectious Diseases and Infection Control, Yamagata Prefectural Central Hospital, Yamagata, Japan. 632551432@qq.com.
Cameron HurstPathogen Hunter's Research Team, Department of Infectious Diseases and Infection Control, Yamagata Prefectural Central Hospital, Yamagata, Japan.
Peter N MonkDepartment of Infection, Immunity and Cardiovascular Disease, University of Sheffield Medical School, Sheffield, UK.
Mohan AmarasiriPathogen Hunter's Research Team, Department of Infectious Diseases and Infection Control, Yamagata Prefectural Central Hospital, Yamagata, Japan.
Phatthranit PhattharapornjaroenFaculty of Health Science Technology, Chulabhorn Royal Academy, Bangkok, 10210, Thailand.
William Graham Fox DitchamSchool of Medicine, Faculty of Health and Medical Sciences, The University of Western Australia, Nedlands, WA, Australia.
Thin Sandi HtunLaboratory of Host Defense, World Premier Institute-Immunology Frontier Research Center (WPI-IFReC), Osaka University, Suita, Osaka, 565-0871, Japan.
Sirirat Luk-InDepartment of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Bangkok, Thailand.
Yoshitaka ShimotaiDepartment of Infectious Diseases, Faculty of Medicine, Yamagata University, Yamagata, Japan.
Natharin NgamwongsatitDepartment of Clinical Sciences and Public Health, Faculty of Veterinary Science, Mahidol University, Nakhon Pathom, Thailand.
Hitoshi IshikawaYamagata Prefectural University of Health Sciences, Kamiyanagi, Yamagata, 990-2212, Japan.
Naveen Kumar Devanga RagupathiBiofilms and Antimicrobial Resistance Consortium of ODA receiving countries, The University of Sheffield, Sheffield, UK.
Daniel PletzerDepartment of Microbiology and Immunology, University of Otago, 720 Cumberland St., Dunedin, 9054, New Zealand.
Talerngsak KanjanabuchDivision of Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Aisha KhatibDepartment of Family and Community Medicine, University of Toronto, Toronto, ON, Canada.
Kazuhiko MiyanagaDivision of Bacteriology, School of Medicine, Jichi Medical University, Tochigi, Japan.
Longzhu CuiDivision of Bacteriology, School of Medicine, Jichi Medical University, Tochigi, Japan.
Kenji ShibuyaTokyo Foundation for Policy Research, Minato-ku, Tokyo, Japan.
Paul G HigginsInstitute for Medical Microbiology, Immunology and Hygiene, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Anthony KicicTelethon Kids Institute, University of Western Australia, Nedlands, WA, 6009, Australia.
Parichart HongsingDepartment of Infectious Diseases, Faculty of Medicine, Yamagata University, Yamagata, Japan. parichart.hon@mfu.ac.th.
Jinxin ZhaoDepartment of Microbiology, Monash Biomedicine Discovery Institute, Monash University, Clayton, VIC, 3800, Australia.
Shuichi AbeDepartment of Infectious Diseases and Infection Control, Yamagata Prefectural Central Hospital, Yamagata, Japan. abeshu@icloud.com.
Hiroshi HamamotoDepartment of Infectious Diseases, Faculty of Medicine, Yamagata University, Yamagata, Japan. hamamoto@med.id.yamagata-u.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Phage therapy is a promising approach against multidrug-resistant infections, yet systemic administration can lead to incomplete cures. We investigated the distribution, immune responses, and efficacy of the therapeutic phage KPP10 delivered via intranasal or intraperitoneal (IP) routes in murine Pseudomonas aeruginosa lung infection models. Intranasal pre-treatment achieved markedly higher localization of KPP10 in the lungs and bronchoalveolar compartment compared to IP delivery. Intranasal administration elicited minimal systemic antibody responses, whereas IP injection triggered significant IgG, IgM, and IgA production. Antibody responses did not differ significantly between doses. In acute and chronic infection models, intranasal KPP10 significantly improved survival (p < 0.01) and reduced lung bacterial loads relative to IP injection. Importantly, IP treatment was associated with bacterial rebound after day 14 in chronic infection, whereas intranasal dosing sustained bacterial clearance. These findings demonstrate that intranasal delivery enhances pulmonary localization, minimizes antibody-mediated neutralization, and provides superior therapeutic efficacy, highlighting its potential as a more effective route for phage therapy against P. aeruginosa lung infections.

Indexed as

Antibodies, BacterialAntibodies, NeutralizingPhage TherapyPseudomonas aeruginosaPseudomonas InfectionsPseudomonas PhagesAdministration, IntranasalAnimalsDisease Models, AnimalFemaleLungMiceAntibodies, BacterialAntibodies, NeutralizingAntibody-mediated neutralizationChronic pulmonary Pseudomonas aeruginosa infectionsIntranasal phage treatment

Identifiers

PMID41108387

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.